|
1
|
Barondes SH, Cooper DN, Gitt MA and
Leffler H: Galectins. Structure and function of a large family of
animal lectins. J Biol Chem. 269:20807–20810. 1994.PubMed/NCBI
|
|
2
|
Powell JT and Whitney PL: Postnatal
development of rat lung. Changes in lung lectin, elastin,
acetylcholinesterase and other enzymes. Biochem J. 188:1–8. 1980.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Buttery R, Monaghan H, Salter DM and Sethi
T: Galectin-3: Differential expression between small-cell and
non-small-cell lung cancer. Histopathology. 44:339–344. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cummings RD and Liu FT: Chapter 33
GalectinsEssentials of Glycobiology. 2nd edition. Varki A, Cummings
RD, Esko JD, et al: Cold Spring Harbor Laboratory Press; La Jolla,
California: 2009
|
|
5
|
Hsu YL, Wu CY, Hung JY, Lin YS, Huang MS
and Kuo PL: Galectin-1 promotes lung cancer tumor metastasis by
potentiating integrin α6β4 and Notch1/Jagged2 signaling pathway.
Carcinogenesis. 34:1370–1381. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ebrahim AH, Alalawi Z, Mirandola L,
Rakhshanda R, Dahlbeck S, Nguyen D, Jenkins M, Grizzi F, Cobos E,
Figueroa JA and Chiriva-Internati M: Galectins in cancer:
Carcinogenesis, diagnosis and therapy. Ann Transl Med.
2:882014.PubMed/NCBI
|
|
7
|
Thijssen VL, Heusschen R, Caers J and
Griffioen AW: Galectin expression in cancer diagnosis and
prognosis: A systematic review. Biochim Biophys Acta. 1855:235–247.
2015.PubMed/NCBI
|
|
8
|
Elola MT, Wolfenstein-Todel C, Troncoso
MF, Vasta GR and Rabinovich GA: Galectins: Matricellular
glycan-binding proteins linking cell adhesion, migration and
survival. Cell Mol Life Sci. 64:1679–1700. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Compagno D, Jaworski FM, Gentilini L,
Contrufo G, Pérez González I, Elola MT, Pregi N, Rabinovich GA and
Laderach DJ: Galectins: Major signaling modulators inside and
outside the cell. Curr Mol Med. 14:630–651. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Varki A, Cummings RD, Esko JD, Freeze HH,
Stanley P, Bertozzi CR, Hart GW and Etzler ME: Essentials of
Glycobiology. 2nd. (eds). Cold Spring Harbor Laboratory Press; Cold
Spring Harbor (NY): 2019
|
|
11
|
Belo AI, van der Sar AM, Tefsen B and van
Die I: Galectin-4 reduces migration and metastasis formation of
pancreatic cancer cells. PLoS One. 8:e659572013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Irie A, Yamauchi A, Kontani K, Kihara M,
Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H and
Hirashima M: Galectin-9 as a prognostic factor with antimetastatic
potential in breast cancer. Clin Cancer Res. 11:2962–2968. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Choufani G, Nagy N, Saussez S, Marchant H,
Bisschop P, Burchert M, Danguy A, Louryan S, Salmon I, Gabius HJ,
et al: The levels of expression of galectin-1, galectin-3, and the
Thomsen-Friedenreich antigen and their binding sites decrease as
clinical aggressiveness increases in head and neck cancers. Cancer.
86:2353–2363. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gillenwater A, Xu XC, el-Naggar AK,
Clayman GL and Lotan R: Expression of galectins in head and neck
squamous cell carcinoma. Head Neck. 18:422–432. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cindolo L, Benvenuto G, Salvatore P, Pero
R, Salvatore G, Mirone V, Prezioso D, Altieri V, Bruni CB and
Chiariotti L: Galectin-1 and galectin-3 expression in human bladder
transitional-cell carcinomas. Int J Cancer. 84:39–43. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van den Brule FA, Buicu C, Berchuck A,
Bast RC, Deprez M, Liu FT, Cooper DN, Pieters C, Sobel ME and
Castronovo V: Expression of the 67-kD laminin receptor, galectin-1,
and galectin-3 in advanced human uterine adenocarcinoma. Hum
Pathol. 27:1185–1191. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang J, Zhu L, Cai Y, Suo J and Jin J:
Role of downregulation of galectin-9 in the tumorigenesis of
gastric cancer. Int J Oncol. 45:1313–1320. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang J, Jin MS, Kong F, Cao D, Ma HX, Jia
Z, Wang YP, Suo J and Cao X: Decreased galectin-9 and increased
Tim-3 expression are related to poor prognosis in gastric cancer.
PLoS One. 8:e817992013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Okada K, Shimura T, Suehiro T, Mochiki E
and Kuwano H: Reduced galectin-3 expression is an indicator of
unfavorable prognosis in gastric cancer. Anticancer Res.
26:1369–1376. 2006.PubMed/NCBI
|
|
20
|
Pinho SS and Reis CA: Glycosylation in
cancer: Mechanisms and clinical implications. Nat Rev Cancer.
15:540–555. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu FT and Rabinovich GA: Galectins as
modulators of tumour progression. Nat Rev Cancer. 5:29–41. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dimitroff CJ: Galectin-Binding
O-glycosylations as regulators of malignancy. Cancer Res.
75:3195–3202. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Campion CG, Labrie M, Lavoie G and
St-Pierre Y: Expression of galectin-7 is induced in breast cancer
cells by mutant p53. PLoS One. 8:e724682013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu X, Ding M, Yu ML, Feng MX, Tan LJ and
Zhao FK: Identification of galectin-7 as a potential biomarker for
esophageal squamous cell carcinoma by proteomic analysis. BMC
Cancer. 10:2902010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tsai CJ, Sulman EP, Eifel PJ, Jhingran A,
Allen PK, Deavers MT and Klopp AH: Galectin-7 levels predict
radiation response in squamous cell carcinoma of the cervix.
Gynecol Oncol. 131:645–649. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim SJ, Hwang JA, Ro JY, Lee YS and Chun
KH: Galectin-7 is epigenetically-regulated tumor suppressor in
gastric cancer. Oncotarget. 4:1461–1471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hayashi T, Saito T, Fujimura T, Hara K,
Takamochi K, Mitani K, Mineki R, Kazuno S, Oh S, Ueno T, et al:
Galectin-4, a novel predictor for lymph node metastasis in lung
adenocarcinoma. PLoS One. 8:e818832013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Barrow H, Guo X, Wandall HH, Pedersen JW,
Fu B, Zhao Q, Chen C, Rhodes JM and Yu LG: Serum galectin-2, −4 and
−8 are greatly increased in colon and breast cancer patients and
promote cancer cell adhesion to blood vascular endothelium. Clin
Cancer Res. 17:7035–7046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ding YM, Dong JH, Chen LL and Zhang HD:
Increased expression of galectin-1 is associated with human oral
squamous cell carcinoma development. Oncol Rep. 21:983–987.
2009.PubMed/NCBI
|
|
30
|
Chung H, Kim B, Jung SH, Won KJ, Jiang X,
Lee CK, Lim SD, Yang SK, Song KH and Kim HS: Does phosphorylation
of cofilin affect the progression of human bladder cancer? BMC
Cancer. 13:452013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Makino K, Kawamura K, Sato W, Kawamura N,
Fujimoto T and Terada Y: Inhibition of uterine sarcoma cell growth
through suppression of endogenous tyrosine kinase B signaling. PLoS
One. 7:e410492012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Camby I, Belot N, Rorive S, Lefranc F,
Maurage CA, Lahm H, Kaltner H, Hadari Y, Ruchoux MM, Brotchi J, et
al: Galectins are differentially expressed in supratentorial
pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and
glioblastomas and significantly modulate tumor astrocyte migration.
Brain Pathol. 11:12–26. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheng CL, Hou HA, Lee MC, Liu CY, Jhuang
JY, Lai YJ, Lin CW, Chen HY, Liu FT, Chou WC, et al: Higher bone
marrow LGALS3 expression is an independent unfavorable prognostic
factor for overall survival in patients with acute myeloid
leukemia. Blood. 121:3172–3180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Endo K, Kohnoe S, Tsujita E, Watanabe A,
Nakashima H, Baba H and Maehara Y: Galectin-3 expression is a
potent prognostic marker in colorectal cancer. Anticancer Res.
25:3117–3121. 2005.PubMed/NCBI
|
|
35
|
Chen J, Zhou SJ, Zhang Y, Zhang GQ, Zha
TZ, Feng YZ and Zhang K: Clinicopathological and prognostic
significance of galectin-1 and vascular endothelial growth factor
expression in gastric cancer. World J Gastroenterol. 19:2073–2079.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim HJ, Jeon HK, Cho YJ, Park YA, Choi JJ,
Do IG, Song SY, Lee YY, Choi CH, Kim TJ, et al: High galectin-1
expression correlates with poor prognosis and is involved in
epithelial ovarian cancer proliferation and invasion. Eur J Cancer.
48:1914–1921. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Croci DO, Morande PE, Dergan-Dylon S,
Borge M, Toscano MA, Stupirski JC, Bezares RF, Avalos JS, Narbaitz
M, Gamberale R, et al: Nurse-like cells control the activity of
chronic lymphocytic leukemia B cells via galectin-1. Leukemia.
27:1413–1416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nakamura M, Inufusa H, Adachi T, Aga M,
Kurimoto M, Nakatani Y, Wakano T, Nakajima A, Hida JI, Miyake M, et
al: Involvement of galectin-3 expression in colorectal cancer
progression and metastasis. Int J Oncol. 15:143–148.
1999.PubMed/NCBI
|
|
39
|
Strik HM, Deininger MH, Frank B,
Schluesener HJ and Meyermann R: Galectin-3: Cellular distribution
and correlation with WHO-grade in human gliomas. J Neurooncol.
53:13–20. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kuo PL, Hung JY, Huang SK, Chou SH, Cheng
DE, Jong YJ, Hung CH, Yang CJ, Tsai YM, Hsu YL and Huang MS: Lung
cancer-derived galectin-1 mediates dendritic cell anergy through
inhibitor of DNA binding 3/IL-10 signaling pathway. J Immunol.
186:1521–1530. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Saussez S, Glinoer D, Chantrain G, Pattou
F, Carnaille B, André S, Gabius HJ and Laurent G: Serum galectin-1
and galectin-3 levels in benign and malignant nodular thyroid
disease. Thyroid. 18:705–712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vereecken P, Boudjeltia Zouaoui K, Debray
C, Awada A, Legssyer I, Sales F, Petein M, Vanhaeverbeek M, Ghanem
G and Heenen M: High serum galectin-3 in advanced melanoma:
Preliminary results. Clin Exp Dermatol. 31:105–109. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Išić T, Savin S, Cvejić D, Marečko I,
Tatić S, Havelka M and Paunović I: Serum Cyfra 21.1 and galectin-3
protein levels in relation to immunohistochemical cytokeratin 19
and galectin-3 expression in patients with thyroid tumors. J Cancer
Res Clin Oncol. 136:1805–1812. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ouyang J, Plütschow A, von Strandmann
Pogge E, Reiners KS, Ponader S, Rabinovich GA, Neuberg D, Engert A
and Shipp MA: Galectin-1 serum levels reflect tumor burden and
adverse clinical features in classical Hodgkin lymphoma. Blood.
121:3431–3433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Vereecken P, Awada A, Suciu S, Castro G,
Morandini R, Litynska A, Lienard D, Ezzedine K, Ghanem G and Heenen
M: Evaluation of the prognostic significance of serum galectin-3 in
American Joint Committee on Cancer stage III and stage IV melanoma
patients. Melanoma Res. 19:316–320. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Iurisci I, Tinari N, Natoli C, Angelucci
D, Cianchetti E and Iacobelli S: Concentrations of galectin-3 in
the sera of normal controls and cancer patients. Clin Cancer Res.
6:1389–1393. 2000.PubMed/NCBI
|
|
47
|
Barrow H, Rhodes JM and Yu LG:
Simultaneous determination of serum galectin-3 and −4 levels
detects metastases in colorectal cancer patients. Cell Oncol
(Dordr). 36:9–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gaida MM, Bach ST, Günther F, Baseras B,
Tschaharganeh DF, Welsch T, Felix K, Bergmann F, Hänsch GM and
Wente MN: Expression of galectin-3 in pancreatic ductal
adenocarcinoma. Pathol Oncol Res. 18:299–307. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Watanabe M, Takemasa I, Kaneko N, Yokoyama
Y, Matsuo E, Iwasa S, Mori M, Matsuura N, Monden M and Nishimura O:
Clinical significance of circulating galectins as colorectal cancer
markers. Oncol Rep. 25:1217–1226. 2011.PubMed/NCBI
|
|
50
|
Saussez S, Lorfevre F, Lequeux T, Laurent
G, Chantrain G, Vertongen F, Toubeau G, Decaestecker C and Kiss R:
The determination of the levels of circulating galectin-1 and −3 in
HNSCC patients could be used to monitor tumor progression and/or
responses to therapy. Oral Oncol. 44:86–93. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tsai MJ, Yang CJ, Kung YT, Sheu CC, Shen
YT, Chang PY, Huang MS and Chiu HC: Metformin decreases lung cancer
risk in diabetic patients in a dose-dependent manner. Lung Cancer.
86:137–143. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang Y, Wang H, Wang J, Bao L, Wang L,
Huo J and Wang X: Global analysis of chromosome 1 genes among
patients with lung adenocarcinoma, squamous carcinoma, large-cell
carcinoma, small-cell carcinoma, or non-cancer. Cancer Metastasis
Rev. 34:249–264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhou X, Li D, Wang X, Zhang B, Zhu H and
Zhao J: Galectin-1 is overexpressed in CD133+ human lung
adenocarcinoma cells and promotes their growth and invasiveness.
Oncotarget. 6:3111–3122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chung LY, Tang SJ, Sun GH, Chou TY, Yeh
TS, Yu SL and Sun KH: Galectin-1 promotes lung cancer progression
and chemoresistance by upregulating p38 MAPK, ERK, and
cyclooxygenase-2. Clin Cancer Res. 18:4037–4047. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
O'Driscoll L, Linehan R, Liang YH, Joyce
H, Oglesby I and Clynes M: Galectin-3 expression alters adhesion,
motility and invasion in a lung cell line (DLKP), in vitro.
Anticancer Res. 22:3117–3125. 2002.PubMed/NCBI
|
|
57
|
Chung LY, Tang SJ, Wu YC, Sun GH, Liu HY
and Sun KH: Galectin-3 augments tumor initiating property and
tumorigenicity of lung cancer through interaction with β-catenin.
Oncotarget. 6:4936–4952. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kuo HY, Hsu HT, Chen YC, Chang YW, Liu FT
and Wu CW: Galectin-3 modulates the EGFR signalling-mediated
regulation of Sox2 expression via c-Myc in lung cancer.
Glycobiology. 26:155–165. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Demers M, Rose AA, Grosset AA, Biron-Pain
K, Gaboury L, Siegel PM and St-Pierre Y: Overexpression of
galectin-7, a myoepithelial cell marker, enhances spontaneous
metastasis of breast cancer cells. Am J Pathol. 176:3023–3031.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Reticker-Flynn NE, Malta DF, Winslow MM,
Lamar JM, Xu MJ, Underhill GH, Hynes RO, Jacks TE and Bhatia SN: A
combinatorial extracellular matrix platform identifies
cell-extracellular matrix interactions that correlate with
metastasis. Nat Commun. 3:11222012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Nobumoto A, Nagahara K, Oomizu S, Katoh S,
Nishi N, Takeshita K, Niki T, Tominaga A, Yamauchi A and Hirashima
M: Galectin-9 suppresses tumor metastasis by blocking adhesion to
endothelium and extracellular matrices. Glycobiology. 18:735–744.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kadowaki T, Arikawa T, Shinonaga R, Oomizu
S, Inagawa H, Soma G, Niki T and Hirashima M: Galectin-9 signaling
prolongs survival in murine lung-cancer by inducing macrophages to
differentiate into plasmacytoid dendritic cell-like macrophages.
Clin Immunol. 142:296–307. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Danguy A, Camby I and Kiss R: Galectins
and cancer. Biochim Biophys Acta. 1572:285–293. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Cheng DE, Chang WA, Hung JY, Huang MS and
Kuo PL: Involvement of IL10 and granulocyte colonystimulating
factor in the fate of monocytes controlled by galectin-1. Mol Med
Rep. 10:2389–2394. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kuo PL, Huang MS, Cheng DE, Hung JY, Yang
CJ and Chou SH: Lung cancer-derived galectin-1 enhances tumorigenic
potentiation of tumor-associated dendritic cells by expressing
heparin-binding EGF-like growth factor. J Biol Chem. 287:9753–9764.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Schulkens IA, Heusschen R, van den
Boogaart V, van Suylen RJ, Dingemans AM, Griffioen AW and Thijssen
VL: Galectin expression profiling identifies galectin-1 and
Galectin-9Δ5 as prognostic factors in stage I/II non-small cell
lung cancer. PLoS One. 9:e1079882014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Carlini MJ, Roitman P, Nuñez M, Pallotta
MG, Boggio G, Smith D, Salatino M, Joffé ED, Rabinovich GA and
Puricelli LI: Clinical relevance of galectin-1 expression in
non-small cell lung cancer patients. Lung Cancer. 84:73–78. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kuo P, Bratman SV, Shultz DB, von Eyben R,
Chan C, Wang Z, Say C, Gupta A, Loo BW Jr, Giaccia AJ, et al:
Galectin-1 mediates radiation-related lymphopenia and attenuates
NSCLC radiation response. Clin Cancer Res. 20:5558–5569. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mathieu A, Saal I, Vuckovic A, Ransy V,
Vereerstraten P, Kaltner H, Gabius HJ, Kiss R, Decaestecker C,
Salmon I and Remmelink M: Nuclear galectin-3 expression is an
independent predictive factor of recurrence for adenocarcinoma and
squamous cell carcinoma of the lung. Mod Pathol. 18:1264–1271.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wang T, Chu Z, Lin H, Jiang J, Zhou X and
Liang X: Galectin-3 contributes to cisplatin-induced myeloid
derived suppressor cells (MDSCs) recruitment in Lewis lung
cancer-bearing mice. Mol Biol Rep. 41:4069–4076. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wu SW, Yu L, Zhou L, Cheng ZN and Tao YS:
Expression of Gal-3 and CD82/KAI1 proteins in non-small cell lung
cancer and their clinical significance. Zhonghua Zhong Liu Za Zhi.
35:124–128. 2013.(In Chinese). PubMed/NCBI
|
|
72
|
Huflejt ME and Leffler H: Galectin-4 in
normal tissues and cancer. Glycoconj J. 20:247–255. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Rumilla KM, Erickson LA, Erickson AK and
Lloyd RV: Galectin-4 expression in carcinoid tumors. Endocr Pathol.
17:243–249. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhu H, Pei HP, Zeng S, Chen J, Shen LF,
Zhong MZ, Yao RJ and Shen H: Profiling protein markers associated
with the sensitivity to concurrent chemoradiotherapy in human
cervical carcinoma. J Proteome Res. 8:3969–3976. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Biron-Pain K, Grosset AA, Poirier F,
Gaboury L and St-Pierre Y: Expression and functions of galectin-7
in human and murine melanomas. PLoS One. 8:e633072013. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Caulet-Maugendre S, Birolleau S, Corbineau
H, Bassen R, Desrues B, Bidon N, Delaval P, Ramée MP, Brichory F
and Dazord L: Immunohistochemical expression of the intracellular
component of galectin-8 in squamous cell metaplasia of the
bronchial epithelium in neoplastic and benign processes. Pathol Res
Pract. 197:797–801. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Gopalkrishnan RV, Roberts T, Tuli S, Kang
D, Christiansen KA and Fisher PB: Molecular characterization of
prostate carcinoma tumor antigen-1, PCTA-1, a human galectin-8
related gene. Oncogene. 19:4405–4416. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Bassen R, Brichory F, Caulet-Maugendre S,
Bidon N, Delaval P, Desrues B and Dazord L: Expression of Po66-CBP,
a type-8 galectin, in different healthy, tumoral and peritumoral
tissues. Anticancer Res. 19:5429–5433. 1999.PubMed/NCBI
|
|
79
|
Bidon-Wagner N and Le Pennec JP: Human
galectin-8 isoforms and cancer. Glycoconj J. 19:557–563. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Henno S, Brichory F, Langanay T, Desrues
B, Bidon N, Delaval P, Ramee MP, Dazord L and Caulet-Maugendre S:
Expression of Po66-CBP, a galectin-8, in different types of primary
and secondary broncho-pulmonary tumors. Oncol Rep. 9:177–180.
2002.PubMed/NCBI
|
|
81
|
Dazord L, Bourel D, Martin A, Lecorre R,
Bourguet P, Bohy J, Saccavini JC, Delaval P, Louvet M and Toujas L:
A monoclonal antibody (Po66) directed against human lung squamous
cell carcinoma immunolocalization of tumour xenografts in nude
mice. Cancer Immunol Immunother. 24:263–268. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Nagahara K, Arikawa T, Oomizu S, Kontani
K, Nobumoto A, Tateno H, Watanabe K, Niki T, Katoh S, Miyake M, et
al: Galectin-9 increases Tim-3+ dendritic cells and
CD8+ T cells and enhances antitumor immunity via
galectin-9-Tim-3 interactions. J Immunol. 181:7660–7669. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Perillo NL, Marcus ME and Baum LG:
Galectins: Versatile modulators of cell adhesion, cell
proliferation and cell death. J Mol Med (Berl). 76:402–412. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Hughes RC: Galectins as modulators of cell
adhesion. Biochimie. 83:667–676. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Heinrich EL, Walser TC, Krysan K, Liclican
EL, Grant JL, Rodriguez NL and Dubinett SM: The inflammatory tumor
microenvironment, epithelial mesenchymal transition and lung
carcinogenesis. Cancer Microenviron. 5:5–18. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Tsai MJ, Chang WA, Huang MS and Kuo PL:
Tumor microenvironment: A new treatment target for cancer. ISRN
Biochem. 2014:3519592014. View Article : Google Scholar : PubMed/NCBI
|
